Skip to content
Bromodiphenhydramine
Ambenyl, Ambodryl, Bromanyl (bromodiphenhydramine) is a small molecule pharmaceutical. Bromodiphenhydramine was first approved as Ambodryl on 1982-01-01. It is used to treat allergic rhinitis perennial, anxiety disorders, cough, motion sickness, and nausea amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
nervous system diseasesD009422
skin and connective tissue diseasesD017437
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
mental disordersD001523
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bromodiphenhydramine hydrochloride
Tradename
Company
Number
Date
Products
AMBODRYLPfizerN-007984 DISCN1982-01-01
1 products
Hide discontinued
Bromodiphenhydramine hydrochloride
+
Codeine phosphate
Tradename
Company
Number
Date
Products
AMBENYLForest LaboratoriesN-009319 DISCN1984-01-10
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
allergic rhinitis perennialEFO_1001417D012221J30.89
anxiety disordersEFO_0006788D001008F41.1
coughHP_0012735D003371R05
motion sicknessD009041T75.3
nauseaHP_0002018D009325R11.0
parkinson diseaseEFO_0002508D010300G20
sleep initiation and maintenance disordersD007319F51.01
urticariaEFO_0005531D014581L50
vertigoD014717H81.39
vomitingHP_0002013D014839R11.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
R06: Antihistamines for systemic use
R06A: Antihistamines for systemic use
R06AA: Aminoalkyl ethers, systemic antihistamines
R06AA01: Bromazine
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E111225
Parkinson diseaseD010300EFO_0002508G20224
SchizophreniaD012559EFO_0000692F20112
Glucose intoleranceD018149HP_0000833R73.0311
Diabetic neuropathiesD003929EFO_100078311
HypertensionD006973EFO_0000537I1011
HyperaldosteronismD006929HP_0011736E2611
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients2113
Insulin resistanceD007333EFO_0002614112
HyperprolactinemiaD006966E22.111
OverweightD050177E66.311
Feeding behaviorD00524711
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian hyperstimulation syndromeD01647122
ObesityD009765EFO_0001073E66.9112
Type 1 diabetes mellitusD003922EFO_0001359E1011
Ischemic strokeD000083242111
Traumatic brain injuriesD000070642S06111
Cerebral hemorrhageD002543111
Subarachnoid hemorrhageD013345EFO_0000713I60111
Subdural hematomaD006408HP_0100309111
FeverD005334HP_0001945R50.9111
Intellectual disabilityD008607F7311
Show 3 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Anorexia nervosaD000856EFO_0004215F50.011
AdenomyosisD062788EFO_1001757N80.011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic painD059350HP_001253211
FibromyalgiaD005356EFO_0005687M79.111
Parkinsonian disordersD020734HP_000130011
Graves ophthalmopathyD049970EFO_100146611
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBROMODIPHENHYDRAMINE
INNbromazine
Description
Bromazine is a tertiary amino compound that is the 4-bromobenzhydryl ether of 2-(dimethylamino)ethanol. An antihistamine with antimicrobial properties, it is used in the control of cutaneous allergies. It has a role as an antimicrobial agent, a muscarinic antagonist and a H1-receptor antagonist. It is a tertiary amino compound and an organobromine compound. It contains a bromazine hydrochloride.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1
Identifiers
PDB
CAS-ID118-23-0
RxCUI19759
ChEMBL IDCHEMBL1201245
ChEBI ID59177
PubChem CID2444
DrugBankDB01237
UNII IDT032BI7727 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 40 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,618 adverse events reported
View more details